The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $32.66

Today's change-0.60 -1.80%
Updated August 28 4:03 PM EDT. Delayed by at least 15 minutes.
 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $32.66

Today's change-0.60 -1.80%
Updated August 28 4:03 PM EDT. Delayed by at least 15 minutes.

Pfizer Inc down (U.S.)$0.60

Pfizer Inc closed sharply lower Friday, dropping (U.S.)$0.60 or 1.80% to (U.S.)$32.66. Shares have lost 2.62% over the last five days, but have gained 4.85% over the last year to date. This security has outperformed the S&P 500 by 11.56% during the last year.

Key company metrics

  • Open(U.S.) $33.30
  • Previous close(U.S.) $33.26
  • High(U.S.) $33.36
  • Low(U.S.) $32.50
  • Bid / Ask(U.S.) $32.53 / (U.S.) $32.73
  • YTD % change+4.85%
  • Volume33,447,975
  • Average volume (10-day)30,456,958
  • Average volume (1-month)26,209,620
  • Average volume (3-month)23,585,706
  • 52-week range(U.S.) $27.51 to (U.S.) $36.46
  • Beta0.87
  • Trailing P/E23.16×
  • P/E 1 year forward16.15×
  • Forward PEG2.87×
  • Indicated annual dividend(U.S.) $1.12
  • Dividend yield3.43%
  • Trailing EPS(U.S.) $1.41
Updated August 28 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.56%

Based on its net profit margin of 18.56%, Pfizer Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 28, 201506/28/2015Mar 29, 201503/29/2015Dec 31, 201412/31/2014Sep 28, 201409/28/2014
Revenue11,85310,86413,11812,361
Total other revenue--------
Total revenue11,85310,86413,11812,361
Gross profit9,6909,03510,43310,006
Total cost of revenue2,1631,8292,6852,355
Total operating expense8,0997,70111,2158,621
Selling / general / administrative3,3863,1043,9813,556
Research & development1,7341,8853,2091,802
Depreciation / amortization872940949972
Interest expense (income), net operating--------
Unusual expense (income)290170531265
Other operating expenses, total-346-227-140-329
Operating income3,7543,1631,9033,740
Interest income (expense), net non-operating-278-309-353-343
Gain (loss) on sale of assets191752153
Other--------
Income before tax3,5393,0821,8033,587
Income after tax2,6342,3761,2582,676
Income tax, total905706545911
Net income2,6262,3751,2292,667
Total adjustments to net income00-1-1
Net income before extra. items2,6252,3701,2512,670
Minority interest-9-6-7-6
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2,6252,3701,2502,669
Inc. avail. to common incl. extra. items2,6262,3751,2282,666
Diluted net income2,6262,3751,2282,666
Dilution adjustment00----
Diluted weighted average shares6,2436,2926,3736,403
Diluted EPS excluding extraordinary itemsvalue per share0.420.380.200.42
Dividends per sharevalue per share0.280.280.260.26
Diluted normalized EPSvalue per share0.460.370.280.45